購物車 
-
雙氯西林鈉
- names：
Dicloxacillin Sodium hydrate
- CAS號：
13412-64-1
MDL Number： MFCD00056865 - MF(分子式)： C19H18Cl2N3NaO6S MW(分子量)： 510.32
- EINECS:206-444-3 Reaxys Number:
- Pubchem ID:23675786 Brand:BIOFOUNT
雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)是雙氯西林的鈉鹽形式，雙氯西林鈉是一種廣譜，半合成的β-內(nèi)酰胺，具有抗細(xì)菌和β-內(nèi)酰胺酶的活性。雙氯西林鈉與位于細(xì)菌細(xì)胞壁內(nèi)膜上的青霉素結(jié)合蛋白（PBP）結(jié)合。雙氯西林鈉還能抑制肽聚糖（細(xì)菌細(xì)胞壁的關(guān)鍵成分）的交聯(lián)。這導(dǎo)致細(xì)菌細(xì)胞壁合成的抑制，并最終引起細(xì)胞裂解。
| 貨品編碼 | 規(guī)格 | 純度 | 價格 (￥) | 現(xiàn)價(￥) | 特價(￥) | 庫存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000227-50mg | 50mg | 98.94% | ￥ 487.00 | ￥ 487.00 | 1-3days | ￥ 0.00 |
- 大包裝詢價 提供各種包裝，敬請垂詢
- 收藏商品 商品點(diǎn)評 加入購物車 立即購買
| 中文別名 | 雙氯西林鈉(13412-64-1);全氟丁基磺酸鋰;雙氯青霉素鈉鹽水合物;雙氯西林鈉一水合物;BRL1702; BRL 1702；BRL-1702；P 1011；P-1011；P1011; 3-（2,6-二氯苯基）-5-甲基-4-異惡唑基青霉素;雙氯西林鈉水合物VETRAN;雙氯西林鈉EPD（CRM標(biāo)準(zhǔn)）;雙氯西林USP（CRM標(biāo)準(zhǔn)）;雙氯西林鈉（WHO（標(biāo)準(zhǔn)）） -Thia-1-azabicyclo3.2.0heptane-2-carbox； |
| 英文別名 | Dicloxacillin Sodium hydrate(13412-64-1);Dicloxacillin sodium salt monohydrate;BRL1702; BRL 1702; BRL-1702; P 1011; P-1011; P1011; 3-(2,6-DICHLOROPHENYL)-5-METHYL-4-ISOXAZOLYL PENICILLIN;DICLOXACILLIN SODIUM SALT HYDRATE VETRAN;DICLOXACILLIN SODIUM EPD(CRM STANDARD);DICLOXACILLIN SODIUM USP(CRM STANDARD);DICLOXACILLIN SODIUM WHO(CRM STANDARD);4-Thia-1-azabicyclo3.2.0heptane-2-carbox; |
| CAS號 | 13412-64-1 |
| Inchi | InChI=1S/C19H17Cl2N3O5S.Na/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24;/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28);/q;+1/p-1/t13-,14+,17-;/m1./s1 |
| InchiKey | GXOMMGAFBINOJY-SLINCCQESA-M |
| 分子式 Formula | C19H18Cl2N3NaO6S |
| 分子量 Molecular Weight | 510.32 |
| 溶解度Solubility | 生物體外In Vitro:H2O : 25 mg/mL(48.99 mM;Need ultrasonic) |
| 性狀 | 白色至類白色結(jié)晶性粉末,Power |
| 儲藏條件 Storage conditions | -20°C 3 years，4°C 2 years ，In solvent -80°C 6 months ， -20°C 1 month |
雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)毒理性質(zhì)：
| 生物 | 測試類型 | 路線 | 劑量 | 影響 | 參考 |
| man | TDLo | oral | 71 mg/kg/5D-I (71 mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN; GASTROINTESTINAL: OTHER CHANGES; LIVER: JAUNDICE, CHOLESTATIC | Journal of Clinical Gastroenterology., 8(77), 1986 |
| rat | LD50 | oral | 3579 mg/kg (3579 mg/kg) | Toxicology and Applied Pharmacology., 18(185), 1971 [PMID:5542824] | |
| rat | LD50 | intraperitoneal | 630 mg/kg (630 mg/kg) | Arzneimittel-Forschung. Drug Research., 15(322), 1965 [PMID:5174841] | |
| rat | LD50 | intravenous | 520 mg/kg (520 mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA; GASTROINTESTINAL: OTHER CHANGES; LIVER: OTHER CHANGES | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] |
| mouse | LD50 | oral | 4560 mg/kg (4560 mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA; GASTROINTESTINAL: OTHER CHANGES; LIVER: OTHER CHANGES | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] |
| mouse | LD50 | intraperitoneal | 1 gm/kg (1000 mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA; GASTROINTESTINAL: OTHER CHANGES; LIVER: OTHER CHANGES | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] |
| dog | LD50 | oral | >3 gm/kg (3000 mg/kg) | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] | |
| rabbit | LD50 | oral | >5 gm/kg (5000 mg/kg) | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] | |
| rabbit | LD50 | intravenous | 600 mg/kg (600 mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA; GASTROINTESTINAL: OTHER CHANGES; LIVER: OTHER CHANGES | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] |
| mouse | LD50 | subcutaneous | 1100 mg/kg (1100 mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA; GASTROINTESTINAL: OTHER CHANGES; LIVER: OTHER CHANGES | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] |
| mouse | LD50 | intravenous | 875 mg/kg (875 mg/kg) | LUNGS, THORAX, OR RESPIRATION: DYSPNEA; GASTROINTESTINAL: OTHER CHANGES; LIVER: OTHER CHANGES | Japanese Journal of Antibiotics., 21(274), 1968 [PMID:5304362] |
雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags；雙氯西林鈉試劑,雙氯西林鈉雜質(zhì),雙氯西林鈉合成,雙氯西林鈉溶解度,雙氯西林鈉密度,雙氯西林鈉旋光度,雙氯西林鈉閃點(diǎn),雙氯西林鈉熔點(diǎn),雙氯西林鈉結(jié)構(gòu)式,雙氯西林鈉購買,
| 產(chǎn)品說明 | 雙氯西林鈉(13412-64-1,Dicloxacillin sodium salt monohydrate)是青霉素類的一種窄譜β-內(nèi)酰胺抗生素,用于治療易感的革蘭氏陽性細(xì)菌引起的感染 |
| Introduction | 雙氯西林鈉(13412-64-1,Dicloxacillin sodium salt monohydrate)is a narrowpectrum βactam antibiotic of the penicillin class, is used to treat infections caused by susceptible Gramositive bacteria, |
| Application1 | 雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)active against betaactamaseroducing organisms such as Staphylococcus aureus. |
| Application2 | 雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)對革蘭氏陽性細(xì)菌等產(chǎn)生的β-內(nèi)酰胺酶的生物（如金黃色葡萄球菌）具有活性。 |
| Application3 |
雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)藥理學(xué)：
1、雙氯西林鈉(β-內(nèi)酰胺化合物雙氯西林的一水合鈉鹽)形式可用作抗生素，尤其是針對革蘭氏陽性細(xì)菌的抗生素，在生物學(xué)研究中也具有重要意義。
2、Dicloxacillin Sodium hydrate (Dicloxacillin sodium salt monohydrate) 是青霉素類的窄譜β內(nèi)酰胺抗生素, 可用于革蘭氏陽性菌感染的研究, 有效對抗β-內(nèi)酰胺酶產(chǎn)生的微生物如金黃色葡萄球菌。
3、雙氯西林鈉是雙氯西林的鈉鹽形式，它是一種廣譜，半合成的β-內(nèi)酰胺，具有抗細(xì)菌和β-內(nèi)酰胺酶的活性。雙氯西林鈉與位于細(xì)菌細(xì)胞壁內(nèi)膜上的青霉素結(jié)合蛋白（PBP）結(jié)合。它還能抑制肽聚糖（細(xì)菌細(xì)胞壁的關(guān)鍵成分）的交聯(lián)。這導(dǎo)致細(xì)菌細(xì)胞壁合成的抑制，并最終引起細(xì)胞裂解。
4、雙氯西林鈉是抗菌劑，雙氯西林鈉可以抑制細(xì)菌生長或繁殖的物質(zhì)。
1、雙氯西林鈉(β-內(nèi)酰胺化合物雙氯西林的一水合鈉鹽)形式可用作抗生素，尤其是針對革蘭氏陽性細(xì)菌的抗生素，在生物學(xué)研究中也具有重要意義。
2、Dicloxacillin Sodium hydrate (Dicloxacillin sodium salt monohydrate) 是青霉素類的窄譜β內(nèi)酰胺抗生素, 可用于革蘭氏陽性菌感染的研究, 有效對抗β-內(nèi)酰胺酶產(chǎn)生的微生物如金黃色葡萄球菌。
3、雙氯西林鈉是雙氯西林的鈉鹽形式，它是一種廣譜，半合成的β-內(nèi)酰胺，具有抗細(xì)菌和β-內(nèi)酰胺酶的活性。雙氯西林鈉與位于細(xì)菌細(xì)胞壁內(nèi)膜上的青霉素結(jié)合蛋白（PBP）結(jié)合。它還能抑制肽聚糖（細(xì)菌細(xì)胞壁的關(guān)鍵成分）的交聯(lián)。這導(dǎo)致細(xì)菌細(xì)胞壁合成的抑制，并最終引起細(xì)胞裂解。
4、雙氯西林鈉是抗菌劑，雙氯西林鈉可以抑制細(xì)菌生長或繁殖的物質(zhì)。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過程中防止吸入、食入，做好安全防護(hù) |
雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)危害標(biāo)識：
| 象形圖 |  |
| 信號 | Danger |
| GHS危險(xiǎn)說明 | Aggregated GHS information provided by 46 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
| H315 (91.3%): Causes skin irritation [Warning Skin corrosion/irritation] | |
| H317 (10.87%): May cause an allergic skin reaction [Warning Sensitization, Skin] | |
| H319 (91.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] | |
| H334 (97.83%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] | |
| H335 (91.3%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] | |
| Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. | |
| 防范說明代碼 | P261, P264, P271, P272, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P312, P321, P332+P313, P333+P313, P337+P313, P342+P311, P362, P363, P403+P233, P405, and P501 |
| (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Jusko WJ, et al. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics. 1975 Dec;56(6):1038-44. |
| Miranda-Novales G, et al. In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains. Ann Clin |
| Second-derivative spectrophotometric assay of mixtures of dicloxacillin sodium and ampicillin sodium in pharmaceuticals PMID 3244108; Journal of pharmaceutical sciences 1988 Dec; 77(12):1042-6 Name ma |
| Bacteriology of acute otitis media in Japanese children PMID 6336890; American journal of diseases of children (1960) 1983 Feb; 137(2):152-4 Name matches: ampicillin sodium dicloxacillin sodium |
| Soft-tissue infections of ampicillin-resistant Haemophilus influenzae type b. The use of ampicillin and nafcillin in their treatment PMID 6972160; American journal of diseases of children (1960) 1981 |
雙氯西林鈉(13412-64-1,Dicloxacillin Sodium hydrate,Dicloxacillin sodium salt monohydrate)參考文獻(xiàn)：
1.Selective spectrophotometric determination of phenolic beta-lactam antibiotics.
Salem H1, Saleh GA. J Pharm Biomed Anal. 2002 Jun 15;28(6):1205-13.
Two simple and selective spectrophotometric methods were developed for the quantitative determination of cefoperazone sodium, cefadroxil monohydrate, cefprozil anhydrous and amoxicillin trihydrate in pure forms as well as in their pharmaceutical formulations. The methods are based on the selective oxidation of these drugs with either Ce (IV) or Fe (III) in acid medium to give an intense yellow coloured product (lambda(max)=397 nm). The reaction conditions were studied and optimized. Beer's plots were obeyed in a general concentration range of 5-30 microg ml(-1) with correlation coefficients not less than 0.9979 for the four drugs with the two reagents. The methods are successfully applied to the analysis of pharmaceutical formulations containing amoxicillin, either alone or in combination with potassium clavulanate, flucloxacillin or dicloxacillin. They were also applied to the analysis of the other three studied drugs in vials, capsules, tablets and suspensions with good recovery; percent ranged from 99.
2.Bacteriology of acute otitis media in Japanese children.
Fujita K, Iseki K, Yoshioka H, Sasaki T, Ando T, Nakamura M. Am J Dis Child. 1983 Feb;137(2):152-4.
Bacteriologic investigations were performed on 100 children with acute otitis media by culturing the fluid from a myringotomy site. Patients ranged in age from 7 months to 14 years, and 91 were younger than 6 years old. Bacterial isolates were yielded from cultures in 83 cases, and mixtures of two or three organisms were obtained from 15 patients. Among the total of 100 isolates, the most predominant organism was Streptococcus pneumoniae (28), followed by Hemophilus influenzae (26), Staphylococcus aureus (19), and Streptococcus pyogenes (six). Minimal inhibitory concentrations (MICs) of ampicillin sodium against S pneumoniae and H influenzae were 0.016 to 0.032 and 0.25 to 0.5 mg/L, respectively. None of the strains of H influenzae were resistant to ampicillin. The MICs of dicloxacillin sodium, cephalexin monohydrate, cefaclor, and erythromycin to H influenzae were 8 to 32, 8 to 16, 2 to 8, and 2 to 8 mg/L, respectively. The preferred drug for acute otitis media would be ampicillin in Japan, but we have to consider antistaphylococcal antibiotics for the patients who do not respond to 48 hours of treatment.
3.Sodium dicloxacillin monohydrate: an anti-staphylococcus antibiotic.
Keefe TJ, Christie GJ. Acta Chir Plast. 1973;15(1):904 passim.
1.Selective spectrophotometric determination of phenolic beta-lactam antibiotics.
Salem H1, Saleh GA. J Pharm Biomed Anal. 2002 Jun 15;28(6):1205-13.
Two simple and selective spectrophotometric methods were developed for the quantitative determination of cefoperazone sodium, cefadroxil monohydrate, cefprozil anhydrous and amoxicillin trihydrate in pure forms as well as in their pharmaceutical formulations. The methods are based on the selective oxidation of these drugs with either Ce (IV) or Fe (III) in acid medium to give an intense yellow coloured product (lambda(max)=397 nm). The reaction conditions were studied and optimized. Beer's plots were obeyed in a general concentration range of 5-30 microg ml(-1) with correlation coefficients not less than 0.9979 for the four drugs with the two reagents. The methods are successfully applied to the analysis of pharmaceutical formulations containing amoxicillin, either alone or in combination with potassium clavulanate, flucloxacillin or dicloxacillin. They were also applied to the analysis of the other three studied drugs in vials, capsules, tablets and suspensions with good recovery; percent ranged from 99.
2.Bacteriology of acute otitis media in Japanese children.
Fujita K, Iseki K, Yoshioka H, Sasaki T, Ando T, Nakamura M. Am J Dis Child. 1983 Feb;137(2):152-4.
Bacteriologic investigations were performed on 100 children with acute otitis media by culturing the fluid from a myringotomy site. Patients ranged in age from 7 months to 14 years, and 91 were younger than 6 years old. Bacterial isolates were yielded from cultures in 83 cases, and mixtures of two or three organisms were obtained from 15 patients. Among the total of 100 isolates, the most predominant organism was Streptococcus pneumoniae (28), followed by Hemophilus influenzae (26), Staphylococcus aureus (19), and Streptococcus pyogenes (six). Minimal inhibitory concentrations (MICs) of ampicillin sodium against S pneumoniae and H influenzae were 0.016 to 0.032 and 0.25 to 0.5 mg/L, respectively. None of the strains of H influenzae were resistant to ampicillin. The MICs of dicloxacillin sodium, cephalexin monohydrate, cefaclor, and erythromycin to H influenzae were 8 to 32, 8 to 16, 2 to 8, and 2 to 8 mg/L, respectively. The preferred drug for acute otitis media would be ampicillin in Japan, but we have to consider antistaphylococcal antibiotics for the patients who do not respond to 48 hours of treatment.
3.Sodium dicloxacillin monohydrate: an anti-staphylococcus antibiotic.
Keefe TJ, Christie GJ. Acta Chir Plast. 1973;15(1):904 passim.
對不起，暫無產(chǎn)品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國際市場的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
驗(yàn)動物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽（K+）設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測定。D-熒光素的質(zhì)量和純度對于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11
如何選BSA（牛血清白蛋白）
如何選BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多種形式，如何選擇適合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常見問題
牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實(shí)驗(yàn)室中是通用的，可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51
